Filter By Category
Archives
Share on -
COFROGLIPTIN
Generic Name: COFROGLIPTIN
ABSTRACT -
Cofrogliptin is a long-acting, once-weekly oral dipeptidyl peptidase-4 (DPP-4) inhibitor under development for type 2 diabetes mellitus. By inhibiting DPP-4, it prevents the degradation of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon. Its extended half-life enables weekly dosing, potentially improving patient adherence compared to daily DPP-4 inhibitors.
DOSAGE -
Oral tablet, once weekly; dose range evaluated in clinical trials approximately 25–100 mg per week; specific approved dose pending regulatory review.
SIDE EFFECTS-
- Nasopharyngitis
- Upper respiratory tract infection
- Headache
- Nausea
- Arthralgia
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Skin rash
- Urticaria
- Angioedema
- Anaphylaxis (rare, class effect)
DRUG INTERACTIONS-
- Low hypoglycaemia risk as monotherapy; risk increases with insulin or sulfonylureas
- No significant CYP-based interactions expected
- Monitor renal function if combining with nephrotoxic agents
PREAUTONS–
- Dose adjustment in renal impairment
- Discontinue if pancreatitis suspected
- Not for type 1 diabetes
- Monitor for joint pain (arthralgia — class effect)
WARNINGS –
- Acute pancreatitis risk reported with DPP-4 inhibitor class
- Bullous pemphigoid reported rarely — discontinue if suspected
- Heart failure hospitalisations: class signal to consider in high-risk patients
Share on -
. Developed by